Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of James Hardie Industries plc regarding a class action lawsuit due to alleged false statements and concealment of adverse facts related to the company's North America segment [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from May 20, 2025, to August 18, 2025 [3]. - Allegations include that James Hardie's North America segment experienced deteriorating consumer demand and that growth was primarily driven by overstocking rather than actual consumer demand, leading to excessive inventory at distributors [3]. Shareholder Information - Shareholders are encouraged to register for the class action by December 23, 2025, to potentially be appointed as lead plaintiffs [4]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Insights - Ardent Health, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company reported a $43 million reduction in revenue and a $54 million increase in professional liability reserves in its Q3 2025 financial results [2] - Following the financial disclosures, Ardent's stock experienced a significant decline during pre-market trading [3] Financial Performance - Ardent Health disclosed a $43 million decrease in revenue due to changes in accounting estimates regarding accounts receivable [2] - The company also announced a $54 million increase in professional liability reserves related to claims in New Mexico [2] Market Reaction - The stock price of Ardent Health fell significantly in pre-market trading on November 13, 2025, following the release of its financial results [3]

Core Insights - Bitdeer Technologies Group is under investigation for possible violations of federal securities laws by Levi & Korsinsky [1] - The company reported a significant earnings miss for Q3 2025, with an earnings per share of -$1.28 compared to the consensus estimate of -$0.22 [2] - Bitdeer announced delays in the development of its next-generation Seal 04 ASIC chip, which may impact future performance [2] - Following the earnings report and news of the delays, Bitdeer's stock price dropped over 14% on November 11, 2025 [2] Company Performance - Bitdeer reported unaudited financial results for Q3 2025, highlighting a substantial loss in earnings per share [2] - The company faced significant operational challenges, particularly with the delay in the development of its ASIC chip [2] Market Reaction - The stock price of Bitdeer fell by more than 14% in response to the negative earnings report and the announcement of delays [2]

Core Insights - Fiserv, Inc. is a global provider of financial services technology, offering services such as payment processing, risk management, and data analytics, and is set to go public on NASDAQ [1] - The Schall Law Firm is investigating Fiserv for potential securities law violations related to misleading statements and undisclosed information following a disappointing third-quarter earnings report [2][6] - Fiserv's CEO acknowledged that previous forecasts were overly optimistic, leading to a 43% drop in stock price on the day of the earnings report [3][6] Financial Performance - Fiserv's stock is currently priced at $114.23, with fluctuations between a low of $112.54 and a high of $114.23 on the day [4] - Over the past year, the stock has reached a high of $188.85 and a low of $109.115, with a market capitalization of approximately $116.2 billion [4] - Today's trading volume for FISV is 20,051,164 shares, indicating significant investor interest amid ongoing challenges [5][6]

Company Overview - Beyond Meat, Inc. specializes in plant-based meat alternatives, including products like the Beyond Burger, and utilizes non-GMO ingredients [3]. Allegations and Financial Impact - On October 24, 2025, Beyond Meat announced a significant non-cash impairment charge on certain assets, which led to a stock price drop of over 23% [4]. - Following the announcement, the company delayed its third-quarter earnings release on November 3, 2025, resulting in an additional decline of 16.52% in its share price [4]. Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws related to Beyond Meat, stemming from allegations of providing misleading business information to investors [1].

Core Insights - Stride, Inc. is under investigation for possible violations of federal securities laws following disappointing enrollment numbers and guidance despite beating earnings expectations [1][2] - The company's stock price dropped significantly after the earnings report, indicating market reaction to the negative outlook [3] Financial Performance - Stride reported its first quarter fiscal 2026 earnings on October 28, 2025, with earnings exceeding expectations [2] - However, enrollment numbers and forward-looking guidance were significantly below market expectations, leading to concerns about the company's future performance [2] Market Reaction - Following the earnings report, Stride's stock price fell by $68.51 per share, opening at $85.02 per share [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging misleading statements and undisclosed risks related to the company's glucose monitoring products [1][3]. Summary by Sections Allegations - The complaint claims that during the class period from July 26, 2024, to September 17, 2025, DexCom made unauthorized design changes to its G6 and G7 glucose monitoring devices, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes allegedly made the G6 and G7 devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [3]. - The enhancements claimed for the G7 device, including its reliability and accuracy, were reportedly overstated by the defendants [3]. - The true scope and severity of the issues with the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [3]. - As a result, the public statements made by the defendants were considered materially false and misleading throughout the relevant period [3]. Next Steps for Shareholders - Shareholders who purchased shares of DXCM during the specified class period are encouraged to register for the class action by December 26, 2025, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Baxter International Inc. following serious safety concerns related to its Novum IQ Large Volume Pump, which has led to significant investor losses and stock price decline [2][3][5]. Group 1: Safety Concerns and Legal Investigation - A Missouri news outlet reported serious safety issues with Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Baxter acknowledged potential under infusion risks in warning letters to customers, disclosing one serious injury linked to the device [4]. - The FDA classified the situation as a Class I recall, indicating a severe risk of serious injury or death, with Baxter reporting 79 serious injury cases and two patient deaths associated with the device [4]. Group 2: Stock Price Impact - Following the announcement of a voluntary and temporary pause in shipments and installations of the Novum LVP, Baxter's stock price fell by $6.24 per share, or 22.4%, closing at $21.61 per share on July 31, 2025 [5].

NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake†or the "Company†) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On September 28, 2025, MoonLake disclosed the 1 ...

Core Viewpoint - Marex Group plc is under investigation by Faruqi & Faruqi, LLP for potential claims related to allegations made in a report by NINGI Research released on August 5, 2025 [1] Group 1 - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [1] - The investigation pertains to claims against Marex Group plc, which is listed on NASDAQ under the ticker MRX [1]